Editorial: Advances in immunotherapy of hepatic-biliary-pancreatic cancers, volume II

Editorial: Advances in immunotherapy of hepatic-biliary-pancreatic cancers, volume II

Saved in:

Bibliographic Details
Main Authors:	Hu Jiaming, Zhang Minghui, Liu Huiqiang, Zhang Zongli, Xu Yunfei
Format:	Article
Language:	English
Published:	Frontiers Media S.A. 2025-01-01
Series:	Frontiers in Oncology
Subjects:	immunotherapy immune checkpoint inhibitors tyrosine kinase inhibitor hepatocellular carcinoma biliary tract cancer
Online Access:	https://www.frontiersin.org/articles/10.3389/fonc.2024.1537218/full
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Donafenib combined with sintilimab for advanced hepatocellular carcinoma: a single arm phase II trial
by: Xiaoyang Hong, et al.
Published: (2025-02-01)

Real-world short-term outcomes and treatment regimen comparisons in patients with metastatic renal cell carcinoma treated with first-line immune combinations
by: Masato Kikuta, et al.
Published: (2025-01-01)

Best practices in the management of thyroid dysfunction induced by immune checkpoint inhibitors
by: Ichiro Yamauchi, et al.
Published: (2025-01-01)

Neoadjuvant atezolizumab plus bevacizumab prior liver transplantation for hepatocellular carcinoma
by: Parissa Tabrizian, et al.
Published: (2025-02-01)

The Immune Landscape and Its Potential for Immunotherapy in Advanced Biliary Tract Cancer
by: Andry Santoso, et al.
Published: (2024-12-01)

Second-line treatment patterns and outcomes in advanced HCC after progression on atezolizumab/bevacizumab
by: Meng Wu, et al.
Published: (2025-02-01)

Case report: Complete response of recurrent locally advanced basal cell carcinoma following addition of vismodegib to neoadjuvant cemiplimab therapy
by: Chalette Lambert-Swainston, et al.
Published: (2025-01-01)

Editorial: Community series in adenosine pathways in cancer immunity and immunotherapy, volume II
by: Junjiang Fu, et al.
Published: (2025-01-01)

Anti-cancer immunotherapy-related cardiotoxicity: preventable and treatable
by: Wu Helena T., et al.
Published: (2025-01-01)

Vascular Endothelial Growth Factor (VEGF) Family and the Immune System: Activators or Inhibitors?
by: Cristina Maria Failla, et al.
Published: (2024-12-01)

Avelumab + axitinib treatment in older patients with advanced renal cell carcinoma in Japan: Subgroup analyses of post‐marketing surveillance data by age
by: Mototsugu Oya, et al.
Published: (2025-01-01)

A Bibliometric Analysis of Medullary Thyroid Carcinoma From 2000 to 2022
by: TAN Meijuan, et al.
Published: (2024-07-01)

Protein kinase inhibitors as targeted therapy for glioblastoma: a meta-analysis of randomized controlled clinical trials
by: José Pinto-Fraga, et al.
Published: (2025-02-01)

Progress in immunotherapy for brain metastatic melanoma
by: Shicheng Zheng, et al.
Published: (2025-01-01)

Charlson syndrome index predicted survival in pancreatic cancer patients received immunotherapy
by: Nan Zhang, et al.
Published: (2025-02-01)

Evaluation of Treatment Outcomes Using dNLR and GNRI in Combination Therapy With Atezolizumab and Bevacizumab for Hepatocellular Carcinoma
by: Atsushi Naganuma, et al.
Published: (2025-01-01)

Non-small cell lung cancer and the tumor microenvironment: making headway from targeted therapies to advanced immunotherapy
by: Anna De Lucia, et al.
Published: (2025-02-01)

Did selective kinase inhibitors change the management of patients with radioiodine-refractory thyroid cancer?
by: Tommaso Porcelli, et al.
Published: (2025-02-01)

Advanced breast cancer with pancreatic metastasis responding well to TKIs after ADC failure: Report of a rare case
by: Huiyun Lv, et al.
Published: (2025-02-01)

Risk of hepatocellular carcinoma in Asian patients with primary biliary cholangitis: A nationwide and hospital cohort study
by: Jihye Lim, et al.
Published: (2025-02-01)

The tyrosine kinase inhibitor lenvatinib is oxidized by rat cytochromes P450 and affects their expression in rat liver
by: Indra Radek, et al.
Published: (2024-09-01)

Identification of Epinastine as CD96/PVR inhibitor for cancer immunotherapy
by: Xiangrui Zhang, et al.
Published: (2025-01-01)

Bibliometric analysis of targeted immunotherapy for osteosarcoma-current knowledge, hotspots and future perspectives
by: Yunxiang Hu, et al.
Published: (2025-02-01)

Effects of Food on the Pharmacokinetics and Safety of HA121-28 Tablet, a Novel Multi-Targeting Tyrosine Kinase Inhibitor, in Healthy Chinese Subjects: A Phase I Clinical Trial
by: Liu Y, et al.
Published: (2025-01-01)

Immunotherapy in metastatic renal cell carcinoma: Insights from a Dutch nationwide cohort
by: Hilin Yildirim, et al.
Published: (2025-02-01)

Predicting immunotherapy efficacy in endometrial cancer: focus on the tumor microenvironment
by: Liubov A. Tashireva, et al.
Published: (2025-01-01)

A comprehensive overview of selective and novel fibroblast growth factor receptor inhibitors as a potential anticancer modality
by: Jain Nem Kumar, et al.
Published: (2024-03-01)

Tepotinib for the Treatment of Lung Adenocarcinoma Harboring MET Y1003N Point Mutation: A Case Report
by: Yukihiro Umeda, et al.
Published: (2025-01-01)

Durvalumab and tremelimumab in patients with advanced rare cancer: a multi-centre, non-blinded, open-label phase II basket trialResearch in context
by: Abha A. Gupta, et al.
Published: (2025-01-01)

An open-label study to determine the maximum tolerated dose of oral ESK-440 administered as a single agent in patients with advanced or metastatic solid tumors
by: Russell J. Schilder, et al.
Published: (2025-03-01)

Fluorescence Lifetime Imaging of NAD(P)H in Patients’ Lymphocytes: Evaluation of Efficacy of Immunotherapy
by: Diana V. Yuzhakova, et al.
Published: (2025-01-01)

Hedgehog pathway inhibitors (HHI) combined with radiotherapy and immunotherapy for advanced basal cell carcinoma: a case report
by: Zhuren Ruan, et al.
Published: (2025-12-01)

Screening and identification of host signaling pathways for alleviating influenza-induced production of pro-inflammatory cytokines, IP-10, IL-8, and MCP-1, using a U937 cell-based influenza model
by: Si Chen, et al.
Published: (2025-01-01)

Biliary diseases (<i>Review of the Seventeenth Russian Gastroenterological Week proceedings, October, 10–12, 2011, Moscow</i>)
by: I. V. Mayev, et al.
Published: (2012-06-01)

Effectiveness and safety of pembrolizumab, nivolumab, and atezolizumab as adjuvant therapy for high-risk muscle-invasive urothelial carcinoma: an indirect comparison
by: Wei Chen, et al.
Published: (2025-01-01)

Recent advances in immunotherapy targeting CETP proteins for atherosclerosis prevention
by: Wenhui Hu, et al.
Published: (2025-12-01)

Structural insights into antibody-based immunotherapy for hepatocellular carcinoma
by: Masaud Shah, et al.
Published: (2025-01-01)

Acute kidney injury in patients treated with immune checkpoint inhibitors: a single-center retrospective study
by: Ping Zhou, et al.
Published: (2024-12-01)

Pediatric and adolescent chronic myeloid leukemia: A follow-up study in Western India
by: Sangita A. Vanik, et al.
Published: (2023-07-01)

Case report: A case of type 1 diabetes with diabetic ketoacidosis induced by envafolimab treatment in hepatocellular carcinoma
by: Youjia Li, et al.
Published: (2025-01-01)